Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
Relay Therapeutics, Inc. (RLAY) Chief Financial Officer Thomas Catinazzo sold 1,469 shares of common stock on October 28, 2026, at $18.62 per share. The sale covered income tax withholding obligations upon the vesting of 3,269 restricted stock units on October 27; Catinazzo had no discretion over the sale, which was transacted in accordance with the issuer’s policies regarding RSU vesting. He directly held 103,665 shares after the transaction, including 3,269 shares underlying RSUs. No Rule 10b5-1 plan is reported.
Relay Therapeutics, Inc. (RLAY) President and CEO and director Sanjiv Patel sold 48,199 common shares on October 7, 2026, at a weighted average price of $18.10 per share. The sale was made under a Rule 10b5-1 trading plan adopted October 30, 2025; trades were executed at prices from $17.87 to $18.46 per share. Patel directly held 471,301 shares after the sale. Separate holdings reported for the Patel Family Irrevocable Trust of 2019 and the SSP Irrevocable Trust of 2020 were 199,548 and 687,355 shares, respectively. An independent trustee serves for both trusts, and Patel disclaims beneficial ownership of those shares.
Relay Therapeutics, Inc. (RLAY) Chief Financial Officer Thomas Catinazzo sold 17,511 shares and 206 shares on October 6, 2026. The respective weighted average prices were $18.58 and $19.26 per share; both sales were made under a Rule 10b5-1 trading plan adopted October 30, 2025.
Relay Therapeutics, Inc. (RLAY) reports a proposed sale for Sanjiv Patel’s account of 96,401 common shares, with an aggregate market value of $1,806,554.74. The approximate sale date is October 7, 2026, and Morgan Stanley Smith Barney LLC is listed as broker. The shares are identified as restricted stock units acquired from the issuer on February 10, 2025. Two prior sales labeled 10b5-1 Sales are listed for the preceding three months: 48,199 shares for $913,096.32 on September 8, 2026, and 48,199 shares for $980,049.55 on August 17, 2026.
Relay Therapeutics, Inc. (RLAY) officer Thomas Catinazzo’s Rule 144 notice covers a proposed sale of 93,153 common shares, with an aggregate market value of $1,806,236.67 and an approximate sale date of October 6, 2026. Morgan Stanley Smith Barney LLC is listed as the broker. The shares were acquired upon vesting of restricted and performance stock units from January 29, 2025 through January 26, 2026. The past-three-month sales history lists 17,717 shares on September 8, 2026, valued at $335,593.64, and 17,717 shares on August 14, 2026, valued at $349,652.08; both are identified as 10b5-1 sales. It also lists 1,459 shares on July 28, 2026, valued at $27,151.99.
Relay Therapeutics, Inc. (RLAY) reported that Donald A. Bergstrom, President, R&D, sold 8,530 shares of common stock on September 8, 2026 in an open-market or private transaction at a weighted average price of $18.97 per share, under a Rule 10b5-1 trading plan adopted on October 30, 2025. After this sale, he directly holds 399,130 shares, including 10,025 shares underlying restricted stock units.
Relay Therapeutics, Inc. (RLAY) reports that Chief Financial Officer Thomas Catinazzo sold 17,717 shares of common stock on September 8, 2026 at a weighted average price of $18.94 per share in a sale in the open market or a private transaction. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025 and was executed in multiple trades at prices ranging from $18.34 to $19.25. Following this transaction, Catinazzo beneficially owns 122,851 shares, including 6,538 shares underlying restricted stock units, held directly.
Relay Therapeutics, Inc. (RLAY) President and CEO Sanjiv Patel reported a sale of 48,199 shares of common stock on September 8, 2026 at a weighted average price of $18.94 per share, executed pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025.
After this sale, he holds 519,500 shares directly and additional shares indirectly through family irrevocable trusts, for which he disclaims beneficial ownership.
Relay Therapeutics, Inc. (RLAY) reported that Chief Corporate Development Officer Peter Rahmer sold 4,508 sharesRule 10b5-1 trading plan$20.03 per share223,657 shares6,102 shares underlying restricted stock units
Relay Therapeutics, Inc. (RLAY) reported that entities associated with SoftBank sold 6,000,000 shares of its Common Stock on August 25, 2026, in a sale classified as an open market or private transaction at $19.40 per share. The shares are held of record by SVF Pauling (Cayman) Limited, a wholly owned subsidiary of SoftBank Vision Fund (AIV M2) L.P., with SB Investment Advisers (UK) Limited acting as alternative investment fund manager and exclusively responsible for acquisition, financing, voting and disposal decisions. Following this transaction, the reporting structure indicates 21,904,963 shares of Relay Therapeutics Common Stock remain held indirectly by these entities.